| HOME >> BIOLOGY >> TECHNOLOGY |
8.2.6 Case Study: Novartis and the City of St. Petersburg 87
8.3 India 88
8.3.1 Technology Transfer Legislation and Regulation 88
8.3.2 Technology Transfer Process 89
8.3.3 Policy for Foreign Technology Agreements 91
8.3.4 Challenges in Technology Transfer 91
8.3.5 Trends in Funding for Universities 91
8.3.6 Implications of Increase/Decrease in Funding 92
8.3.7 Case Study: Biocon, Limited and Amylin Pharmaceuticals, Inc. 92
8.4 China 93
8.4.1 Technology Transfer Legislation and Regulation 93
8.4.2 Technology Transfer Process 95
8.4.3 Policy for Foreign Technology Transfer Agreements 96
8.4.4 Challenges in Technology Transfer 97
8.4.5 Trends in Funding for Universities 98
8.4.6 Implications of Increase in Funding 100
8.4.7 Case Studies of Technology Transfer and its Effects on the Pharmaceutical Industry 100
9 Appendix 101
9.1 Industry Definitions 101
9.2 Abbreviations 102
9.3 Research Methodology 106
9.3.1 Coverage 106
9.3.2 Secondary Research 106
9.3.3 Primary Research 107
9.3.4 Expert Panel Validation 107
9.4 Contact Us 107
9.5 Disclaimer 107
9.6 Sources 108
1.1 List of Tables
Table 1: Technology Transfer, The Principle Provisions of an IP License, 2011 50
Table 2: Technology Transfer, The US, Office of Technology Transfer Activities, 2003–2011 70
Table 3: Technology Transfer, Composition of the sources of funding for R&D at the University of Campinas (Unicamp), 2010 83
1.2 List of Figures
Figure 1: Technology Transfer, Reasons for Technology Transfer, 2011 11
Figure 2: Technology Transfer, Model for Transfer Between Public Research Organizations and the Pharmaceutical Industry, 2011 16
Figure 3: Technology Transfer, Drug Discovery and Development Processes, 2011 17
Figure 4: Technology T
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |